latest news

It’s not too late to learn more about the characterization
of monoclonal antibody (MAb) therapeutics

GEN's Heightened Characterization of Therapeutic mAbs Using a Novel Enzyme-Facilitated Middle-Down Approach webinar, originally broadcast on May 15, 2013 is now available for viewing from the GEN archives:

Heightened Characterization of Therapeutic mAbs Using a
Novel Enzyme-Facilitated Middle-Down Approach - Duration: 60 minutes

QED introduces 4 new antibodies that target leukemia and lymphoma markers

QED introduces 4 new antibodies that target leukemia and lymphoma markers: MLL, ENL, AF4, and HGAL. These antibodies are thoroughly characterized and are ideal reagents for studying oncogene expression and regulation.

Increased Demand for Anti-Ids

Evaluating pharmacokinetics or tissue distribution of therapeutic antibodies requires methods that distinguish an administered therapeutic antibody from endogenous immunoglobulins in patient samples. (learn more)